Last reviewed · How we verify
vaccination PNEUMOVAX 23
PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
PNEUMOVAX 23 is a polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children ≥2 years of age, Prevention of pneumococcal pneumonia, bacteremia, and meningitis.
At a glance
| Generic name | vaccination PNEUMOVAX 23 |
|---|---|
| Sponsor | Walvax Biotechnology Co., Ltd. |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharide antigens from 23 different pneumococcal serotypes conjugated or presented to elicit both T-cell and B-cell immune responses. This generates protective antibodies and cellular immunity that prevent invasive pneumococcal disease including pneumonia, bacteremia, and meningitis caused by the included serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in adults and children ≥2 years of age
- Prevention of pneumococcal pneumonia, bacteremia, and meningitis
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or arthralgia
- Headache
- Fatigue
Key clinical trials
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab (PHASE3)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia (PHASE2)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vaccination PNEUMOVAX 23 CI brief — competitive landscape report
- vaccination PNEUMOVAX 23 updates RSS · CI watch RSS
- Walvax Biotechnology Co., Ltd. portfolio CI